AXIM Biotechnologies, Inc. AXIM
0.00 USD 0.00 (+0.00%)
Regular-session close
0.0031 Day range 0.0031
0.002 52-week range 0.029
- YTD
- -72.73%
- 1 year
- -76.92%
News
globenewswire.com VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's
globenewswire.com AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM…
globenewswire.com AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays
businesswire.com AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today…
globenewswire.com Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
globenewswire.com AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
globenewswire.com AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19 SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological,…
globenewswire.com AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board
globenewswire.com AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member
globenewswire.com AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech
globenewswire.com AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological,…
globenewswire.com AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological…
globenewswire.com AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological…
